Investors Targeted in Securities Fraud Suit Against Unicycive Therapeutics

The legal action centers on claims that Unicycive failed to audit its third-party manufacturing facilities, leaving the company without a basis to confirm that FDA-cited deficiencies had been resolved. According to the complaint, these omissions created an undisclosed risk that the regulatory approval for oxylanthanum carbonate (OLC) would face significant delays. Investors allege that the company’s public statements during the class period were materially misleading, resulting in financial damages once the reality of the manufacturing issues reached the market.

Those who purchased UNCY stock during the specified window have until November 2, 2026, to petition the Court to serve as lead plaintiff. While a class has not yet been certified, affected parties may retain counsel of their choice or remain absent members of the class. The Rosen Law Firm is managing the case on a contingency fee basis, meaning participants do not incur out-of-pocket costs. Further information regarding the litigation is available through the firm’s contact channels or by reaching out to Phillip Kim, Esq.